Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 80

1.

Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study.

Bekaii-Saab TS, Ou FS, Ahn DH, Boland PM, Ciombor KK, Heying EN, Dockter TJ, Jacobs NL, Pasche BC, Cleary JM, Meyers JP, Desnoyers RJ, McCune JS, Pedersen K, Barzi A, Chiorean EG, Sloan J, Lacouture ME, Lenz HJ, Grothey A.

Lancet Oncol. 2019 Jun 28. pii: S1470-2045(19)30272-4. doi: 10.1016/S1470-2045(19)30272-4. [Epub ahead of print]

PMID:
31262657
2.

Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine versus FOLFIRINOX in advanced pancreatic cancer: a systematic review.

Chiorean EG, Cheung WY, Giordano G, Kim G, Al-Batran SE.

Ther Adv Med Oncol. 2019 May 19;11:1758835919850367. doi: 10.1177/1758835919850367. eCollection 2019. Review.

3.

Pancreatic Adenocarcinoma, Version 1.2019.

Tempero MA, Malafa MP, Chiorean EG, Czito B, Scaife C, Narang AK, Fountzilas C, Wolpin BM, Al-Hawary M, Asbun H, Behrman SW, Benson AB, Binder E, Cardin DB, Cha C, Chung V, Dillhoff M, Dotan E, Ferrone CR, Fisher G, Hardacre J, Hawkins WG, Ko AH, LoConte N, Lowy AM, Moravek C, Nakakura EK, O'Reilly EM, Obando J, Reddy S, Thayer S, Wolff RA, Burns JL, Zuccarino-Catania G.

J Natl Compr Canc Netw. 2019 Mar 1;17(3):202-210. doi: 10.6004/jnccn.2019.0014.

PMID:
30865919
4.

Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313.

Ramanathan RK, McDonough SL, Philip PA, Hingorani SR, Lacy J, Kortmansky JS, Thumar J, Chiorean EG, Shields AF, Behl D, Mehan PT, Gaur R, Seery T, Guthrie KA, Hochster HS.

J Clin Oncol. 2019 May 1;37(13):1062-1069. doi: 10.1200/JCO.18.01295. Epub 2019 Feb 28.

PMID:
30817250
5.

Biomarker-driven and molecularly targeted therapies for pancreatic adenocarcinoma.

Zhen DB, Coveler A, Zanon S, Reni M, Chiorean EG.

Semin Oncol. 2018 Jun;45(3):107-115. doi: 10.1053/j.seminoncol.2018.05.004. Epub 2018 Jun 5. Review.

PMID:
30391013
6.

The role of GLI-SOX2 signaling axis for gemcitabine resistance in pancreatic cancer.

Jia Y, Gu D, Wan J, Yu B, Zhang X, Chiorean EG, Wang Y, Xie J.

Oncogene. 2019 Mar;38(10):1764-1777. doi: 10.1038/s41388-018-0553-0. Epub 2018 Oct 31.

7.

Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma.

Jamieson SM, Tsai P, Kondratyev MK, Budhani P, Liu A, Senzer NN, Chiorean EG, Jalal SI, Nemunaitis JJ, Kee D, Shome A, Wong WW, Li D, Poonawala-Lohani N, Kakadia PM, Knowlton NS, Lynch CR, Hong CR, Lee TW, Grénman RA, Caporiccio L, McKee TD, Zaidi M, Butt S, Macann AM, McIvor NP, Chaplin JM, Hicks KO, Bohlander SK, Wouters BG, Hart CP, Print CG, Wilson WR, Curran MA, Hunter FW.

JCI Insight. 2018 Aug 23;3(16). pii: 122204. doi: 10.1172/jci.insight.122204. eCollection 2018 Aug 23.

8.

A Phase II Study of Pemetrexed in Patients with Recurrent Thymoma and Thymic Carcinoma.

Gbolahan OB, Porter RF, Salter JT, Yiannoutsos C, Burns M, Chiorean EG, Loehrer PJ Sr.

J Thorac Oncol. 2018 Dec;13(12):1940-1948. doi: 10.1016/j.jtho.2018.07.094. Epub 2018 Aug 16.

PMID:
30121390
9.

Performance status dynamics during treatment with nab-paclitaxel plus gemcitabine versus gemcitabine alone for metastatic pancreatic cancer.

Chiorean EG, Von Hoff D, Wan Y, Margunato-Debay S, Botteman M, Goldstein D.

Cancer Manag Res. 2018 May 31;10:1389-1396. doi: 10.2147/CMAR.S163475. eCollection 2018.

10.

The role of the folate pathway in pancreatic cancer risk.

Chittiboyina S, Chen Z, Chiorean EG, Kamendulis LM, Hocevar BA.

PLoS One. 2018 Feb 23;13(2):e0193298. doi: 10.1371/journal.pone.0193298. eCollection 2018.

11.

Phase I/II study of mocetinostat in combination with gemcitabine for patients with advanced pancreatic cancer and other advanced solid tumors.

Chan E, Chiorean EG, O'Dwyer PJ, Gabrail NY, Alcindor T, Potvin D, Chao R, Hurwitz H.

Cancer Chemother Pharmacol. 2018 Feb;81(2):355-364. doi: 10.1007/s00280-017-3494-3. Epub 2017 Dec 13.

PMID:
29238851
12.

Phase 2 study of treatment selection based on tumor thymidylate synthase expression in previously untreated patients with metastatic colorectal cancer: A trial of the ECOG-ACRIN Cancer Research Group (E4203).

Meropol NJ, Feng Y, Grem JL, Mulcahy MF, Catalano PJ, Kauh JS, Hall MJ, Saltzman JN, George TJ Jr, Zangmeister J, Chiorean EG, Cheema PS, O'Dwyer PJ, Benson AB 3rd.

Cancer. 2018 Feb 15;124(4):688-697. doi: 10.1002/cncr.30967. Epub 2017 Dec 6.

13.

Altered metabolite levels and correlations in patients with colorectal cancer and polyps detected using seemingly unrelated regression analysis.

Chen C, Gowda GAN, Zhu J, Deng L, Gu H, Chiorean EG, Zaid MA, Harrison M, Zhang D, Zhang M, Raftery D.

Metabolomics. 2017 Nov;13(11). pii: 125. doi: 10.1007/s11306-017-1265-0. Epub 2017 Sep 15.

14.

Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

Tempero MA, Malafa MP, Al-Hawary M, Asbun H, Bain A, Behrman SW, Benson AB 3rd, Binder E, Cardin DB, Cha C, Chiorean EG, Chung V, Czito B, Dillhoff M, Dotan E, Ferrone CR, Hardacre J, Hawkins WG, Herman J, Ko AH, Komanduri S, Koong A, LoConte N, Lowy AM, Moravek C, Nakakura EK, O'Reilly EM, Obando J, Reddy S, Scaife C, Thayer S, Weekes CD, Wolff RA, Wolpin BM, Burns J, Darlow S.

J Natl Compr Canc Netw. 2017 Aug;15(8):1028-1061. doi: 10.6004/jnccn.2017.0131.

PMID:
28784865
15.

Phase 2 study of combination SPI-1620 with docetaxel as second-line advanced biliary tract cancer treatment.

Kim R, Chiorean EG, Amin M, Rocha-Lima CMS, Gandhi J, Harris WP, Song T, Portnoy D.

Br J Cancer. 2017 Jul 11;117(2):189-194. doi: 10.1038/bjc.2017.160. Epub 2017 Jun 20.

16.

Phase 1 study of narnatumab, an anti-RON receptor monoclonal antibody, in patients with advanced solid tumors.

LoRusso PM, Gounder M, Jalal SI, André V, Kambhampati SRP, Loizos N, Hall J, Holzer TR, Nasir A, Cosaert J, Kauh J, Chiorean EG.

Invest New Drugs. 2017 Aug;35(4):442-450. doi: 10.1007/s10637-016-0413-0. Epub 2017 Feb 4.

17.

Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.

Burstein HJ, Krilov L, Aragon-Ching JB, Baxter NN, Chiorean EG, Chow WA, De Groot JF, Devine SM, DuBois SG, El-Deiry WS, Epstein AS, Heymach J, Jones JA, Mayer DK, Miksad RA, Pennell NA, Sabel MS, Schilsky RL, Schuchter LM, Tung N, Winkfield KM, Wirth LJ, Dizon DS.

J Clin Oncol. 2017 Apr 20;35(12):1341-1367. doi: 10.1200/JCO.2016.71.5292. Epub 2017 Feb 1. No abstract available.

PMID:
28148207
18.

Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer.

Chiorean EG, Von Hoff DD, Tabernero J, El-Maraghi R, Wee Ma W, Reni M, Harris M, Whorf R, Liu H, Shiansong Li J, Manax V, Romano A, Lu B, Goldstein D.

Br J Cancer. 2016 Oct 25;115(9):e13. doi: 10.1038/bjc.2016.306. Epub 2016 Sep 22. No abstract available.

19.

Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and advanced colorectal cancer.

Saif MW, Knost JA, Chiorean EG, Kambhampati SR, Yu D, Pytowski B, Qin A, Kauh JS, O'Neil BH.

Cancer Chemother Pharmacol. 2016 Oct;78(4):815-24. doi: 10.1007/s00280-016-3134-3. Epub 2016 Aug 26.

PMID:
27566701
20.

Combining NMR and LC/MS Using Backward Variable Elimination: Metabolomics Analysis of Colorectal Cancer, Polyps, and Healthy Controls.

Deng L, Gu H, Zhu J, Nagana Gowda GA, Djukovic D, Chiorean EG, Raftery D.

Anal Chem. 2016 Aug 16;88(16):7975-83. doi: 10.1021/acs.analchem.6b00885. Epub 2016 Aug 1.

21.

Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer.

Chiorean EG, Von Hoff DD, Tabernero J, El-Maraghi R, Ma WW, Reni M, Harris M, Whorf R, Liu H, Li JS, Manax V, Romano A, Lu B, Goldstein D.

Br J Cancer. 2016 Jul 12;115(2):188-94. doi: 10.1038/bjc.2016.185. Epub 2016 Jun 28. Erratum in: Br J Cancer. 2016 Oct 25;115(9):e13.

22.

Phase I Study of Lenalidomide and Sorafenib in Patients With Advanced Hepatocellular Carcinoma.

Shahda S, Loehrer PJ, Clark RS, Spittler AJ, Althouse SK, Chiorean EG.

Oncologist. 2016 Jun;21(6):664-5. doi: 10.1634/theoncologist.2016-0071. Epub 2016 Jun 2.

23.

Localized Pancreatic Cancer: Multidisciplinary Management.

Coveler AL, Herman JM, Simeone DM, Chiorean EG.

Am Soc Clin Oncol Educ Book. 2016;35:e217-26. doi: 10.14694/EDBK_160827. Review.

24.

Positron emission tomography (PET) as a predictive measure in patients with metastatic pancreatic cancer and normal CA19-9 levels at baseline.

Ramanathan RK, Korn RL, Chiorean EG, Liu H, Von Hoff DD.

Ann Oncol. 2016 Aug;27(8):1647-8. doi: 10.1093/annonc/mdw177. Epub 2016 May 30. No abstract available.

25.

CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer.

Chiorean EG, Von Hoff DD, Reni M, Arena FP, Infante JR, Bathini VG, Wood TE, Mainwaring PN, Muldoon RT, Clingan PR, Kunzmann V, Ramanathan RK, Tabernero J, Goldstein D, McGovern D, Lu B, Ko A.

Ann Oncol. 2016 Apr;27(4):654-60. doi: 10.1093/annonc/mdw006. Epub 2016 Jan 22.

26.

Algenpantucel-L immunotherapy in pancreatic adenocarcinoma.

Coveler AL, Rossi GR, Vahanian NN, Link C, Chiorean EG.

Immunotherapy. 2016 Feb;8(2):117-25. doi: 10.2217/imt.15.113. Epub 2016 Jan 20. Review.

PMID:
26787078
27.

Pancreatic cancer: Update on immunotherapies and algenpantucel-L.

McCormick KA, Coveler AL, Rossi GR, Vahanian NN, Link C, Chiorean EG.

Hum Vaccin Immunother. 2016 Mar 3;12(3):563-75. doi: 10.1080/21645515.2015.1093264. Review.

28.

Targeted serum metabolite profiling and sequential metabolite ratio analysis for colorectal cancer progression monitoring.

Zhu J, Djukovic D, Deng L, Gu H, Himmati F, Abu Zaid M, Chiorean EG, Raftery D.

Anal Bioanal Chem. 2015 Oct;407(26):7857-63. doi: 10.1007/s00216-015-8984-8. Epub 2015 Sep 5.

29.

Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies.

Chiorean EG, Coveler AL.

Drug Des Devel Ther. 2015 Jul 7;9:3529-45. doi: 10.2147/DDDT.S60328. eCollection 2015. Review.

30.

Exploring Metabolic Profile Differences between Colorectal Polyp Patients and Controls Using Seemingly Unrelated Regression.

Chen C, Deng L, Wei S, Nagana Gowda GA, Gu H, Chiorean EG, Abu Zaid M, Harrison ML, Pekny JF, Loehrer PJ, Zhang D, Zhang M, Raftery D.

J Proteome Res. 2015 Jun 5;14(6):2492-9. doi: 10.1021/acs.jproteome.5b00059. Epub 2015 May 13.

31.

Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors.

Chiorean EG, Hurwitz HI, Cohen RB, Schwartz JD, Dalal RP, Fox FE, Gao L, Sweeney CJ.

Ann Oncol. 2015 Jun;26(6):1230-7. doi: 10.1093/annonc/mdv144. Epub 2015 Mar 18.

PMID:
25787923
32.

Ocular metastasis of colorectal cancer: An uncommon presentation of a common malignancy.

Khawaja MR, Minturn JT, Spittler AJ, Chiorean EG.

Hematol Oncol Stem Cell Ther. 2015 Dec;8(4):176-80. doi: 10.1016/j.hemonc.2015.02.002. Epub 2015 Mar 10.

33.

A Phase I First-in-Human Study of Enoticumab (REGN421), a Fully Human Delta-like Ligand 4 (Dll4) Monoclonal Antibody in Patients with Advanced Solid Tumors.

Chiorean EG, LoRusso P, Strother RM, Diamond JR, Younger A, Messersmith WA, Adriaens L, Liu L, Kao RJ, DiCioccio AT, Kostic A, Leek R, Harris A, Jimeno A.

Clin Cancer Res. 2015 Jun 15;21(12):2695-703. doi: 10.1158/1078-0432.CCR-14-2797. Epub 2015 Feb 27.

34.

Metabolomics method to comprehensively analyze amino acids in different domains.

Gu H, Du J, Carnevale Neto F, Carroll PA, Turner SJ, Chiorean EG, Eisenman RN, Raftery D.

Analyst. 2015 Apr 21;140(8):2726-34. doi: 10.1039/c4an02386b. Epub 2015 Feb 20.

35.

Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer.

Tabernero J, Chiorean EG, Infante JR, Hingorani SR, Ganju V, Weekes C, Scheithauer W, Ramanathan RK, Goldstein D, Penenberg DN, Romano A, Ferrara S, Von Hoff DD.

Oncologist. 2015 Feb;20(2):143-50. doi: 10.1634/theoncologist.2014-0394. Epub 2015 Jan 12.

36.

Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer.

Borad MJ, Reddy SG, Bahary N, Uronis HE, Sigal D, Cohn AL, Schelman WR, Stephenson J Jr, Chiorean EG, Rosen PJ, Ulrich B, Dragovich T, Del Prete SA, Rarick M, Eng C, Kroll S, Ryan DP.

J Clin Oncol. 2015 May 1;33(13):1475-81. doi: 10.1200/JCO.2014.55.7504. Epub 2014 Dec 15.

37.

An open-label phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancer.

Gordon MS, Robert F, Matei D, Mendelson DS, Goldman JW, Chiorean EG, Strother RM, Seon BK, Figg WD, Peer CJ, Alvarez D, Adams BJ, Theuer CP, Rosen LS.

Clin Cancer Res. 2014 Dec 1;20(23):5918-26. doi: 10.1158/1078-0432.CCR-14-1143. Epub 2014 Sep 26.

38.

Colorectal cancer detection using targeted serum metabolic profiling.

Zhu J, Djukovic D, Deng L, Gu H, Himmati F, Chiorean EG, Raftery D.

J Proteome Res. 2014 Sep 5;13(9):4120-30. doi: 10.1021/pr500494u. Epub 2014 Aug 15.

PMID:
25126899
39.

Adjuvant Gemcitabine and Gemcitabine-based Chemoradiotherapy Versus Gemcitabine Alone After Pancreatic Cancer Resection: The Indiana University Experience.

Khawaja MR, Kleyman S, Yu Z, Howard T, Burns M, Nakeeb A, Loehrer PJ Sr, Cardenes HR, Chiorean EG.

Am J Clin Oncol. 2017 Feb;40(1):42-46. doi: 10.1097/COC.0000000000000115.

PMID:
25121637
40.

Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines.

Tempero MA, Malafa MP, Behrman SW, Benson AB 3rd, Casper ES, Chiorean EG, Chung V, Cohen SJ, Czito B, Engebretson A, Feng M, Hawkins WG, Herman J, Hoffman JP, Ko A, Komanduri S, Koong A, Lowy AM, Ma WW, Merchant NB, Mulvihill SJ, Muscarella P 2nd, Nakakura EK, Obando J, Pitman MB, Reddy S, Sasson AR, Thayer SP, Weekes CD, Wolff RA, Wolpin BM, Burns JL, Freedman-Cass DA.

J Natl Compr Canc Netw. 2014 Aug;12(8):1083-93.

PMID:
25099441
41.

Anticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab.

Tabernero J, Chawla SP, Kindler H, Reckamp K, Chiorean EG, Azad NS, Lockhart AC, Hsu CP, Baker NF, Galimi F, Beltran P, Baselga J.

Target Oncol. 2015 Mar;10(1):65-76. doi: 10.1007/s11523-014-0315-z. Epub 2014 May 11.

42.

Phase 1 pharmacogenetic and pharmacodynamic study of sorafenib with concurrent radiation therapy and gemcitabine in locally advanced unresectable pancreatic cancer.

Chiorean EG, Schneider BP, Akisik FM, Perkins SM, Anderson S, Johnson CS, DeWitt J, Helft P, Clark R, Johnston EL, Spittler AJ, Deluca J, Bu G, Shahda S, Loehrer PJ, Sandrasegaran K, Cardenes HR.

Int J Radiat Oncol Biol Phys. 2014 Jun 1;89(2):284-91. doi: 10.1016/j.ijrobp.2014.02.024. Epub 2014 Apr 11.

PMID:
24726286
43.

Contribution of environment and genetics to pancreatic cancer susceptibility.

Hocevar BA, Kamendulis LM, Pu X, Perkins SM, Wang ZY, Johnston EL, DeWitt JM, Li L, Loehrer PJ, Klaunig JE, Chiorean EG.

PLoS One. 2014 Mar 20;9(3):e90052. doi: 10.1371/journal.pone.0090052. eCollection 2014.

44.

Taxanes: impact on pancreatic cancer.

Chiorean EG, Von Hoff DD.

Anticancer Drugs. 2014 May;25(5):584-92. doi: 10.1097/CAD.0000000000000073. Review.

PMID:
24463484
45.

A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRα) monoclonal antibody, in patients with advanced solid tumors.

Chiorean EG, Sweeney C, Youssoufian H, Qin A, Dontabhaktuni A, Loizos N, Nippgen J, Amato R.

Cancer Chemother Pharmacol. 2014 Mar;73(3):595-604. doi: 10.1007/s00280-014-2389-9. Epub 2014 Jan 23.

PMID:
24452395
46.

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.

Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF.

N Engl J Med. 2013 Oct 31;369(18):1691-703. doi: 10.1056/NEJMoa1304369. Epub 2013 Oct 16.

47.

A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma.

Beatty GL, Torigian DA, Chiorean EG, Saboury B, Brothers A, Alavi A, Troxel AB, Sun W, Teitelbaum UR, Vonderheide RH, O'Dwyer PJ.

Clin Cancer Res. 2013 Nov 15;19(22):6286-95. doi: 10.1158/1078-0432.CCR-13-1320. Epub 2013 Aug 27.

48.

Phase 1 dose-escalation, pharmacokinetic, and cerebrospinal fluid distribution study of TAK-285, an investigational inhibitor of EGFR and HER2.

LoRusso P, Venkatakrishnan K, Chiorean EG, Noe D, Wu JT, Sankoh S, Corvez M, Sausville EA.

Invest New Drugs. 2014 Feb;32(1):160-70. doi: 10.1007/s10637-013-9988-x. Epub 2013 Jul 2.

49.

Combining hedgehog signaling inhibition with focal irradiation on reduction of pancreatic cancer metastasis.

Gu D, Liu H, Su GH, Zhang X, Chin-Sinex H, Hanenberg H, Mendonca MS, Shannon HE, Chiorean EG, Xie J.

Mol Cancer Ther. 2013 Jun;12(6):1038-48. doi: 10.1158/1535-7163.MCT-12-1030. Epub 2013 Mar 6.

50.

Elevated phospholipase A2 activities in plasma samples from multiple cancers.

Cai H, Chiorean EG, Chiorean MV, Rex DK, Robb BW, Hahn NM, Liu Z, Loehrer PJ, Harrison ML, Xu Y.

PLoS One. 2013;8(2):e57081. doi: 10.1371/journal.pone.0057081. Epub 2013 Feb 22.

Supplemental Content

Loading ...
Support Center